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Abstract 
Advanced-stage primary cutaneous T-cell lymphoma has an unfavorable prognosis and 
low survival rates. Aggressive treatment with chemotherapy is not curative and causes 
considerable side effects. The combination of bexarotene and denileukin diftitox is 
associated with an acceptable safety profile and a likely synergistic effect because 
bexarotene is capable of modulating expression of IL-2 receptor and enhance the 
susceptibility of T-cell leukemia cells to denileukin diftitox. In the case reported here, the 
response to this combined treatment was satisfactory and well tolerated. The patient 
showed a complete regression of pruritus, restlessness, and insomnia. Skin lesions 
improved partially, and lymphadenopathy was reduced and finally disappeared 
completely. 
Case Report 
A 55-year-old man was diagnosed with a 10-year history of stage-IIIA erythrodermic advanced-stage 
primary cutaneous T-cell lymphoma (CTCL; T4N0M0). Initially, he was treated with topical 
corticosteroid cream, psoralen plus UVA phototherapy and IFN-α. The patient did not respond to this 
therapy and was started on a course of bexarotene monotherapy at a dose of 300 mg/m
2/day, achieving a 
marked improvement of his skin lesions. Only few side effects (hypertriglyceridemia, 
hypercholesterolemia, and hyperthyroidism) which were clinically manageable occurred. After 4 years 
of bexarotene treatment during which clinical response was maintained, the patient experienced a 
relapse with skin infiltration of 90% of the total body surface (fig. 1, left), with palmoplantar 
keratoderma (fig. 1, right) and palpable axillary and inguinal lymph nodes. The patient was restless and 
nervous, had generalized pruritus, and was unable to sleep.  
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A skin biopsy confirmed the diagnosis of CTCL without large-cell transformation (fig. 2, left). In 
addition, 20% of the atypical lymphocytes were positive for CD25 expression by immunohistochemistry 
(fig. 2, center). The histological examination of the lymph node biopsy showed extensive infiltration 
(fig. 2, right). A complete blood count revealed the absence of circulating Sézary cells, computed 
tomography indicated no visceral involvement, and bone marrow biopsy revealed no abnormalities. 
Due to the advanced stage of the lymphoma and the appearance of new lesions, denileukin diftitox 
was added to bexarotene therapy. The treatment schedule with intravenous denileukin diftitox was fixed 
at 18 mg/kg/day for the first 3 days of each 21-day cycle for a total of 4 cycles, with previous 
administration of steroid medication (dexamethasone 8 mg). Additionally, antihistamine 
(dexchlorpheniramine maleate 5 mg) and antipyretics (paracetamol 1 g) were administered. After 
infusion, the treatment was completed with adequate intravenous saline hydration in order to reduce 
the incidence of vascular leak syndrome. 
Denileukin diftitox treatment was well tolerated, and no notable infusion-related effects occurred. 
Side effects of bexarotene, such as dyslipidemia and central hypothyroidism, were controlled with oral 
medication. 
The response to this combined treatment was satisfactory. The patient showed a complete regression 
of pruritus, restlessness, and insomnia. Skin lesions improved partially (fig. 3), and lymphadenopathy 
was reduced and finally disappeared. Then, denileukin diftitox administration was stopped, and only 
bexarotene treatment was maintained at 300 mg/m
2/day. 
After 6 months, the patient showed a deterioration of facial skin lesions, with no increase in 
lymphadenopathy, systemic symptoms, or extracutaneous involvement. Currently, the patient receives 
treatment with extracorporeal photopheresis and radiotherapy. 
Discussion 
Bexarotene is a retinoid which is specifically selective for retinoid X receptors. Its 
efficacy for the clinical treatment of CTCL in the initial and advanced stages has been 
proven previously [1, 2]. Dyslipidemia, hypothyroidism, and leukopenia are possible 
adverse drug reactions that may occur in connection with bexarotene [1, 2]. 
Denileukin diftitox is a relatively novel engineered fusion protein obtained from the 
combination of interleukin-2 and the enzymatically active domains of diphtheria toxin 
[3–5]. The therapeutic targets of the protein are neoplastic cells that express interleukin-2 
receptors (IL2R). Although its binding affinity is higher for heterotrimeric proteins of the 
receptors composed of α/p55/CD25, β/p75/CD122, and γ/p64/CD132 chains, it also has 
an effect on intermediate affinity receptors with β and γ chains. The expression of 
different subunits of IL2R is dynamically regulated by specific cytokines and genes 
associated with cellular activation [3–5]. Denileukin diftitox has been used for the 
treatment of several hematologic neoplasms [6, 7], and some clinical trials have identified 
its utility in the treatment of mycosis fungoides and other CTCLs [8–11]. The most 
common adverse reactions include constitutional and gastrointestinal symptoms, acute 
hypersensitivity reactions which can usually be reduced by systemic corticosteroid 
premedication [12, 13], and vascular leak syndrome (hypotension, edema, and 
hypoalbuminemia) [6–13]. Furthermore, denileukin diftitox has been used as 
monotherapy of mycosis fungoides. Olsen et al. [8] obtained an objective response rate of 
30% (10% complete response), with a mean duration of 6.9 months, using dose levels of 
45 or 90 μg/kg/cycle. In a more recent study using the same dosage procedure [9], a 
response rate of 51% was observed (14% complete response). Moreover, in 3 of the 6 
patients with Sézary syndrome included in this clinical trial skin lesions and lymph nodes 
improved.  
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The combination of bexarotene and denileukin diftitox was based on in vitro and in 
vivo studies. These studies have shown that bexarotene positively regulated both p55 and 
p75 subunits of IL2R and enhanced the susceptibility of neoplasm cells to denileukin 
diftitox action [13, 14]. 
A phase-I clinical trial was published including 14 patients with mycosis fungoides at 
different stages (IA–IVB) and combining both drugs: 75–300 mg/day oral bexarotene and 
54 μg/kg/cycle intravenous denileukin diftitox were administered, using systemic 
corticosteroid premedication [13]. In this study, an overall response rate of 67% (33% 
complete responses) was obtained, which is clearly better than the rates observed in 
monotherapy. Regarding adverse reactions, no significant increase in toxicity was 
observed. Although a higher percentage of lymphopenia was observed, it was not possible 
to establish a relationship to the lymphoma, bexarotene, or the combination of both 
drugs. Moreover, the authors observed that the positive regulation of CD25 expression 
was achieved with relatively low levels of bexarotene of at least 150 mg/day. 
Kerl et al. [15] reported a case involving significant regression of a nasal-type 
extranodal natural killer/T-cell lymphoma treated with both bexarotene (150 mg/day) 
and denileukin diftitox (90 μg/kg/cycle). In this case, lesions improved after the first cycle 
of treatment, but the disease progressed when treatment was stopped after a period of 5 
cycles [15]. 
Our patient, who was diagnosed with stage-IIIA erythrodermic CTCL, was treated 
with oral bexarotene (300 mg/day) after not responding to psoralen plus UVA 
phototherapy and IFN-α therapy, and good control of the disease was achieved. After 4 
years of bexarotene monotherapy, skin lesions reappeared, covering 90% of the body 
surface, and lymph nodes were involved as well. Another biopsy of the skin lesions 
confirmed the CTCL diagnosis without large-cell transformation and showed a high 
CD25 expression. At this point, denileukin diftitox was added to the monotherapy (18 
μg/kg/day × 3 days/cycle × 4 cycles). The combination of bexarotene and denileukin 
diftitox was well tolerated. Pruritus and insomnia were reduced, lymphadenopathy 
diminished, and skin lesions improved. 
In conclusion, the combination of bexarotene and denileukin diftitox does not seem to 
significantly increase the adverse reactions associated with monotherapy with each drug, 
and probably a synergistic therapeutic effect can be obtained due to the upregulation of 
IL2R. Nevertheless, randomized clinical trials would be necessary to confirm this 
hypothesis and to establish the most suitable dosing regimen for both drugs. 
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Fig. 1. The patient presented skin infiltration of 90% of the total body surface (left), with palmoplantar 
keratoderma (right). 
 
 
 
Fig. 2. Skin biopsy showing CTCL without large-cell transformation (left, HE, ×200) and CD25 
expression (center, HE, ×400), and lymph node biopsy revealing extensive infiltration of atypical 
lymphocytes (right, HE, ×200). 
 
 
 
Fig. 3. After combined treatment with bexarotene and denileukin diftitox, the skin lesions improved 
partially. 
  
Case Rep Dermatol 2011;3:13–17 
DOI: 10.1159/000324185 
Published online: 
February 5, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
17
References 
1 Duvic M, Martin AG, Kim Y, et al: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the 
treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581–
593. 
2 Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for the treatment of refractory advanced-
stage cutaneous T-cell lymphoma: multinational phase II–III trial results. J Clin Oncol 2001;19:2456–2471. 
3 Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB: Interleukin 2 receptor-targeted 
cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J 
Exp Med 1988;167:612–622. 
4 Waters CA, Snider CE, Itoh K, et al: DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 
receptor-bearing human peripheral blood mononuclear cells. Ann NY Acad Sci 1991;636:403–405. 
5 Williams DP, Snider CE, Strom TB, Murphy JR: Structure/function analysis of interleukin-2-toxin (DAB486-
IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 
1990;265:11885–11889. 
6 Le Maistre CF, Saleh MN, Kuzel TM, et al: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas 
expressing the receptor for interleukin-2. Blood 1998;91:399–405. 
7 Wong BY, Gregory SA, Dang NH: Denileukin diftitox as novel targeted therapy for lymphoid malignancies. 
Cancer Invest 2007;25:495–501. 
8 Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the 
treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376–388. 
9 Chin KM, Foss FM: Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma 
treated with denileukin diftitox. Clin Lymphoma Myeloma 2006;7:199–204. 
10 Hathaway T, Subtil A, Kuo P, Foss F: Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell 
lymphoma. Clin Lymphoma Myeloma 2007;7:541–545. 
11 Assaf C: Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides. Dermatol Clin 
2008;(suppl 1):21–22. 
12 Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T: Biological correlates of acute hypersensitivity 
events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency 
and severity with steroid premedication. Clin Lymphoma 2001;1:298–302. 
13 Foss F, Demierre MF, DiVenuti G: A phase-I trial of bexarotene and denileukin diftitox in patients with 
relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106:454–457. 
14 DiVenuti GM, Foss FM: Phase I dose escalation study of Targretin and Ontak in hematologic malignancies: 
upregulation of IL2R expression by low dose Targretin. Blood 2001;98:601a. 
15 Kerl K, Prins C, Cerroni L, French LE: Regression of extranodal natural killer/T-cell lymphoma, nasal type with 
denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. Br J Dermatol 2006;154:988–991. 